Recent Finacing
Recent Raise
Reglagene develops brain‑penetrant small‑molecule medicines, including oral RGN6024 for glioblastoma and brain metastases, maintains patents for antibody‑drug conjugate prototypes, and participates in a Texas Medical Center cancer accelerator.